These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [15+/-deoxyspergualin, hope for patients with multiple sclerosis?]. Kappos L; Theobald K; Hartung HP Nervenarzt; 1992 Dec; 63(12):768-71; discussion 772. PubMed ID: 1494394 [No Abstract] [Full Text] [Related]
3. Effects of 15-deoxyspergualin on mononuclear cells from kidney recipients. Johansson-Borg A; Ohlman S; Groth CG Transplant Proc; 1992 Feb; 24(1):267-8. PubMed ID: 1539276 [No Abstract] [Full Text] [Related]
4. Local immunosuppression of canine renal allografts with 15-deoxyspergualin. Hughes SE; Xiao S; Perera S; Fluno C; Hasselbarth J; Jayasankar V; Singh J; Del Rosario A; Freed BM; Singh TP; Lempert N; Conti DJ; Gruber SA Transplant Proc; 1996 Aug; 28(4):2054-5. PubMed ID: 8769153 [No Abstract] [Full Text] [Related]
5. 15-Deoxyspergualin: a newly developed immunosuppressive agent and its mechanism of action and clinical effect: a review. Japan Collaborative Transplant Study Group for NKT-01. Amemiya H Artif Organs; 1996 Aug; 20(8):832-5. PubMed ID: 8853792 [TBL] [Abstract][Full Text] [Related]
6. Deoxyspergualin. Mechanism of action studies of a novel immunosuppressive drug. Tepper MA Ann N Y Acad Sci; 1993 Nov; 696():123-32. PubMed ID: 8109823 [No Abstract] [Full Text] [Related]
7. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Dhingra K; Fritsche H; Murray JL; LoBuglio AF; Khazaeli MB; Kelley S; Tepper M; Greene D; Booser D; Buzdar A Adv Exp Med Biol; 1994; 353():193-202. PubMed ID: 7985538 [No Abstract] [Full Text] [Related]
8. Immunosuppressive mechanisms and action of deoxyspergualin in experimental and clinical studies. Japanese Collaborative Transplant Study Group of NKT-01. Amemiya H Transplant Proc; 1995 Feb; 27(1):31-2. PubMed ID: 7879015 [No Abstract] [Full Text] [Related]
9. FK506 and deoxyspergualin: experimental studies and clinical applications. Suzuki S Transpl Immunol; 1994 Sep; 2(3):190-8. PubMed ID: 7528087 [No Abstract] [Full Text] [Related]
10. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Nadler SG; Eversole AC; Tepper MA; Cleaveland JS Ther Drug Monit; 1995 Dec; 17(6):700-3. PubMed ID: 8588244 [TBL] [Abstract][Full Text] [Related]
11. Effect of 15-deoxyspergualin on antibody secretion by specific isotypes producing B-cell hybridomas and myelomas. Sterbenz KG; Tepper MA Transplant Proc; 1994 Dec; 26(6):3218-20. PubMed ID: 7998121 [No Abstract] [Full Text] [Related]
12. Inhibition of antibody production by the immunosuppressive agent, 15-deoxyspergualin. Tepper MA; Petty B; Bursuker I; Pasternak RD; Cleaveland J; Spitalny GL; Schacter B Transplant Proc; 1991 Feb; 23(1 Pt 1):328-31. PubMed ID: 1990547 [No Abstract] [Full Text] [Related]